9 / 9
Notes:
conference
series LLC Ltd
September 18-19, 2018 | Amsterdam, Netherlands
6
th
European Biopharma Congress
Euro Biopharma 2018
Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X
Volume 7
Page 24
Bimal Roy Krishna, Clin Pharmacol Biopharm 2018, Volume:7
DOI: 10.4172/2167-065X-C1-027
Current Clinical Indications of Immunomodulators
I
mmunomodulators have shown great promise in regard to prevention and treatment
of various disorders ranging from autoimmune, inflammation, rheumatoid
arthritis, Crohns Disease and infectious diseases. Several agents exist with different
mechanisms of action, indications and side effect profiles. The two general categories
are Immunosuppressive and Immunostimulatory agents. The goal has been to increase
immune system specificity while minimizing toxicity peripherally and to other organs.
Infectious diseases are considered immunological disorders and neoplastic diseases
are involved in an immunosuppressive state. Immunomodulators are able to stimulate
natural and defensive mechanisms which are of potential clinical benefit. While they
are highly beneficial, their side effects and toxicity profile can often limit their use.
There are also potential drug interactions. This presentation summarizes a number of
immunomodulators with their clinical indications, mechanism of action and toxicity
profiles.
Biography
Bimal Roy Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine,
Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and
Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) fromMonash University inAustralia. He
also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in
UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University
for over seven years. He has contributed to numerous publications and is a Member of a number of organizations
including Fellow-American College of Clinical Pharmacology. His research background is in Maternal and Neonatal
Pharmacology, specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured
syncytiotrophoblast model. Complementary and Alternative Medicine is another area of his interest.
roy.krishna@tun.touro.eduBimal Roy Krishna
Touro University, USA